Literature DB >> 19169012

The medical directorship of renal dialysis facilities under the new Medicare conditions for coverage: challenges and opportunities.

Peter B DeOreo1.   

Abstract

The new Medicare conditions for coverage for providers of end-stage renal disease services provide both a challenge and an opportunity for medical directors. The conditions expect active clinical leadership in quality improvement and the performance of the facility staff and medical staff. These new rules define patient assessment and care planning processes that complement the quality assessment and performance improvement (QAPI) program. Infection control, patient safety and error reduction are given new emphasis. The interdisciplinary team (IDT) under the leadership of the medical director will advance the quality and safety of the patients under their care. Patients' rights and autonomy are stressed. The QAPI/IDT will monitor complaints, satisfaction surveys, and grievances to minimize involuntary discharge. The medical director will report the results of the QAPI program to the governing body. Medical directors will find that participation in renal network quality improvement programs and initiatives will enhance their facility's QAPI program.

Entities:  

Mesh:

Year:  2009        PMID: 19169012     DOI: 10.1159/000167003

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  3 in total

Review 1.  Patient and facility safety in hemodialysis: opportunities and strategies to develop a culture of safety.

Authors:  Renee Garrick; Alan Kliger; Beth Stefanchik
Journal:  Clin J Am Soc Nephrol       Date:  2012-01-26       Impact factor: 8.237

2.  The evolving role of the medical director of a dialysis facility.

Authors:  Franklin W Maddux; Allen R Nissenson
Journal:  Clin J Am Soc Nephrol       Date:  2014-10-02       Impact factor: 8.237

3.  Patient education and care for peritoneal dialysis catheter placement: a quality improvement study.

Authors:  Leslie P Wong; Kalani T Yamamoto; Vijay Reddy; Denise Cobb; Alice Chamberlin; Hien Pham; Sumi J Sun; Madhavi Mallareddy; Miguel Saldivar
Journal:  Perit Dial Int       Date:  2013-07-01       Impact factor: 1.756

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.